Related references
Note: Only part of the references are listed.Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
Bronwen Herbert et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients
P. Costet et al.
ATHEROSCLEROSIS (2010)
The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation
Tohru Noguchi et al.
ATHEROSCLEROSIS (2010)
The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis
Jean Davignon et al.
CURRENT ATHEROSCLEROSIS REPORTS (2010)
Regulatory Effects of Peptides from the Pro and Catalytic Domains of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) on Low-Density Lipoprotein Receptor (LDL-R)
H. Palmer-Smith et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents
Marianne Abifadel et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
Majambu Mbikay et al.
FEBS LETTERS (2010)
A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
Yan G. Ni et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
Jason S. Troutt et al.
JOURNAL OF LIPID RESEARCH (2010)
A new method for measurement of total plasma PCSK9: clinical applications
Genevieve Dubuc et al.
JOURNAL OF LIPID RESEARCH (2010)
Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
Jeffrey D. Browning et al.
JOURNAL OF LIPID RESEARCH (2010)
Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population
Ilaria Guella et al.
JOURNAL OF LIPID RESEARCH (2010)
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
Greg Welder et al.
JOURNAL OF LIPID RESEARCH (2010)
PCSK9 R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease 3 Independent Studies and Meta-Analyses
Marianne Benn et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
Nidhi Gupta et al.
PLOS ONE (2010)
Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins
Kuo-Liong Chien et al.
PHARMACOGENOMICS (2010)
PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
Cedric Langhi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Lipid Treatment Assessment Project 2 A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals
David D. Waters et al.
CIRCULATION (2009)
Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort
John F. Thompson et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2009)
Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels The Coronary Artery Risk Development in Young Adults Study
Chiang-Ching Huang et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2009)
Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?
Dick C. Chan et al.
CLINICAL CHEMISTRY (2009)
PCSK9 as a therapeutic target of dyslipidemia
Nabil G. Seidah
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Mutations and Polymorphisms in the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease
Marianne Abifadel et al.
HUMAN MUTATION (2009)
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Hepatitis C virus cell entry: role of lipoproteins and cellular receptors
Michela E. Burlone et al.
JOURNAL OF GENERAL VIROLOGY (2009)
The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
S. A. Mousavi et al.
JOURNAL OF INTERNAL MEDICINE (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Berberine decreases PCSK9 expression in HepG2 cells
Jamie Cameron et al.
ATHEROSCLEROSIS (2008)
Familial hypercholesterolaemia in Portugal
M. Bourbon et al.
ATHEROSCLEROSIS (2008)
Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population
Eliana Polisecki et al.
ATHEROSCLEROSIS (2008)
Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
Vivienne M. Homer et al.
ATHEROSCLEROSIS (2008)
Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population
Yasuko Miyake et al.
ATHEROSCLEROSIS (2008)
Evidence mandating earlier and more aggressive treatment of hypercholesterolemia
Daniel Steinberg et al.
CIRCULATION (2008)
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment
Gilles Lambert et al.
CLINICAL CHEMISTRY (2008)
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
Cedric Langhi et al.
FEBS LETTERS (2008)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9
Sanae Kourimate et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Characterization of novel mutations in the catalytic domain of the PCSK9 gene
J. Cameron et al.
JOURNAL OF INTERNAL MEDICINE (2008)
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Janice Mayne et al.
LIPIDS IN HEALTH AND DISEASE (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PCSK9 and LDL cholesterol: unravelling the target to design the bullet
Philippe Costet et al.
TRENDS IN BIOCHEMICAL SCIENCES (2008)
Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2
Hyun Jeong Jeong et al.
JOURNAL OF LIPID RESEARCH (2008)
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Holly E. Careskey et al.
JOURNAL OF LIPID RESEARCH (2008)
The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy UK men
Marileia Scartezini et al.
CLINICAL SCIENCE (2007)
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Ian Graham et al.
EUROPEAN HEART JOURNAL (2007)
Serum proprotein convertase subtilisin Kexin type 9 is correlated directly with serum LDL cholesterol
William E. Alborn et al.
CLINICAL CHEMISTRY (2007)
Plasma PCSK9 levels correlate with cholesterol in men but not in women
Janice Mayne et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Morphine inhibits doxorubicin-induced reactive oxygen species generation and nuclear factor κB transcriptional activation in neuroblastoma SH-SY5Y cells
Xin Lin et al.
BIOCHEMICAL JOURNAL (2007)
Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterotemia
Evan A. Stein et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2007)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells
Markey C. McNutt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from the bogalusa heart study)
D. Michael Hallman et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol
Tommaso Fasano et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Molecular biology of PCSK9: its role in LDL metabolism
Jay D. Horton et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: Lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor
Gilles Lambert et al.
ENDOCRINOLOGY (2006)
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Christopher P. Cannon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
KE Berge et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c
P Costet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
KM Timms et al.
HUMAN GENETICS (2004)
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin
E Stein et al.
AMERICAN HEART JOURNAL (2004)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Optimal low-density lipoprotein is 50 to 70 mg/dl - Lower is better and physiologically normal
JH O'Keefe et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Share Paper
